CEOWORLD magazine

5th Avenue, New York, NY 10001, United States
Phone: +1 3479835101
Email: info@ceoworld.biz
CEOWORLD magazine - Latest - Banking and Finance - SAB Biotherapeutics CFO Michael King to Depart for CEO Role at Oncology Firm

Banking and Finance

SAB Biotherapeutics CFO Michael King to Depart for CEO Role at Oncology Firm

SAB Biotherapeutics (NASDAQ: SABS), a clinical-stage biopharmaceutical company, announced that Chief Financial Officer Michael King will leave his position on June 4 to become CEO of a private oncology firm. King will continue to advise SAB until the end of the year. The Board of Directors has initiated a search for his permanent replacement.

In the interim, Mark Conley, Vice President of Finance with 38 years of experience in biotech finance and accounting, will serve as acting CFO. Samuel J. Reich, Chairman and CEO of SAB, expressed gratitude for King’s contributions and optimism for the company’s future as it expands its clinical program for type 1 diabetes (T1D).

King reflected on his time at SAB, expressing respect for the company’s mission and confidence in its continued success, particularly as their lead candidate, SAB-142, progresses in clinical trials. SAB confirmed it is maintaining its fiscal outlook for 2024 and anticipates topline data from its Phase 1 study of SAB-142.

SAB Biotherapeutics specializes in developing human immunoglobulins to treat and prevent immune and autoimmune disorders without needing human donors. Their lead asset, SAB-142, aims to modify the disease course of T1D, potentially delaying onset and preventing progression. The company’s technology involves genetically engineered Transchromosomic (Tc) Bovine™, which produces a diverse array of potent human IgGs.

As SAB navigates the transition following King’s departure, maintaining financial stability and market performance remains crucial. The company has a market capitalization of $24.36 million and a Price to Earnings (P/E) ratio of -0.45, indicating negative earnings expectations. For Q1 2024, SAB reported $2.6 million in revenue and a gross profit margin of 76.2%.

 

Have you read?
Best countries for hiring freelancers.
Highest Paid Big Pharma CEOs And Top Executives.
Best Websites For CEOs, business leaders, and high-net-worth individuals.
Best Executive Search Firms And Consultants in America.
Revealed: Most Powerful Women In The World.


Add CEOWORLD magazine to your Google News feed.
Follow CEOWORLD magazine headlines on: Google News, LinkedIn, Twitter, and Facebook.
Copyright 2024 The CEOWORLD magazine. All rights reserved. This material (and any extract from it) must not be copied, redistributed or placed on any website, without CEOWORLD magazine' prior written consent. For media queries, please contact: info@ceoworld.biz
CEOWORLD magazine - Latest - Banking and Finance - SAB Biotherapeutics CFO Michael King to Depart for CEO Role at Oncology Firm
Anna Siampani
Anna Siampani, Lifestyle Editorial Director at the CEOWORLD magazine, working with reporters covering the luxury travel, high-end fashion, hospitality, and lifestyle industries. As lifestyle editorial director, Anna oversees CEOWORLD magazine's daily digital editorial operations, editing and writing features, essays, news, and other content, in addition to editing the magazine's cover stories, astrology pages, and more. You can reach Anna by mail at anna@ceoworld.biz